行情

LUMO

LUMO

Lumos Pharma
NASDAQ

实时行情|Nasdaq Last Sale

6.92
+0.20
+2.98%
盘后: 6.75 -0.17 -2.46% 19:03 01/21 EST
开盘
6.15
昨收
6.72
最高
7.14
最低
6.15
成交量
4.11万
成交额
--
52周最高
22.49
52周最低
6.15
市值
5,783.31万
市盈率(TTM)
-2.1509
分时
5日
1月
3月
1年
5年
Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
AUSTIN, Texas, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. Wainwright Virtual BIOCONNECT Confe...
GlobeNewswire · 01/05 14:00
Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ...
Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics Pharmaceuticals Inc, Amicus Therapeutics Inc, Merus NV, sells ESSA Pharma Inc, Seres Therapeutics Inc, CM Life...
GuruFocus.com · 2021/12/28 14:38
Lumos Pharma European Patent Office Specification For Co.'s 'DETECTING AND TREATING GROWTH HORMONE DEFICIENCY'
https://data.epo.org/publication-server/pdf-document?pn=3352752&ki=B1&cc=EP
Benzinga · 2021/12/22 17:50
GRTX, ANNX and LUMO among after hour movers
Gainers: Galera Therapeutics (NASDAQ:GRTX) +11%. TFF Pharmaceuticals (NASDAQ:TFFP) +7%. Annexon (NASDAQ:ANNX) +6%. Clarus Therapeutics Holdings (NASDAQ:CRXT) +4%. Tyra Biosciences (NASDAQ:TYRA) +4%. Losers: CalAmp CAMP -14%. Qilian International Holding Gr...
Seekingalpha · 2021/12/21 22:49
Down 16.1% in 4 Weeks, Here's Why Lumos (LUMO) Looks Ripe for a Turnaround
Zacks.com · 2021/11/24 15:00
We're Hopeful That Lumos Pharma (NASDAQ:LUMO) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St. · 2021/11/15 16:14
Minerva Advisors LLC Buys FreightCar America Inc, Nicolet Bankshares Inc, Lumos Pharma Inc, ...
GuruFocus News · 2021/11/12 19:38
Lumos Pharma to Participate in Upcoming Investor Conferences
AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investor conferen...
GlobeNewswire · 2021/11/10 22:06
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解LUMO最新的财务预测,通过LUMO每股收益,每股净资产,每股现金流等数据分析Lumos Pharma近期的经营情况,然后做出明智的投资选择。
分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

16.67%强力推荐
83.33%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测LUMO价格均价为27.17,最高价位35.00,最低价为17.00。
最高35.00
均价27.17
最低17.00
现价6.92
EPS
实际EPS
预期EPS
-0.86-0.64-0.43-0.21
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 102
机构持股: 509.04万
持股比例: 60.91%
总股本: 835.74万
类型机构数股数
增持
7
11.87万
建仓
4
6.15万
减持
9
4.92万
平仓
7
46.75万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-1.82%
制药与医学研究
-1.11%
高管信息
Chairman/Chief Executive Officer/Director
Richard Hawkins
President/Chief Operating Officer/Chief Scientific Officer
John McKew
Chief Financial Officer/Chief Accounting Officer
Lori Lawley
General Counsel
Bradley Powers
Other
David Karpf
Lead Director/Independent Director
Thomas Raffin
Independent Director
An van Es-Johansson
Independent Director
Chad Johnson
Independent Director
Kevin Lalande
Independent Director
Joseph McCracken
Independent Director
Lota Zoth
暂无数据
LUMO 简况
Lumos Pharma Inc是一家处于临床阶段的生物制药公司。该公司专注于识别、收购、开发和商业化罕见病患者的产品和疗法。该公司的主要候选产品是LUM-201,用于治疗儿童生长激素缺乏症(PGHD)和其他罕见内分泌疾病。LUM-201通过促生长激素分泌受体刺激生长激素(GH)。该产品通过增加内源性和脉动性生长激素分泌的幅度,提供了治疗罕见内分泌失调的差异化作用机制。LUM-201是一种口服小分子,是一种用于罕见内分泌疾病的GH促分泌素,其中注射用重组人生长激素(rhGH)已获批准。该公司的产品线包括与生长激素缺乏相关的罕见疾病的开发项目。

微牛提供Lumos Pharma Inc(NASDAQ-LUMO)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的LUMO股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易LUMO股票基本功能。